Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.49 |
| ▸ | MET | P08581 | 6/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | TTK | P33981 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | LIPC | P11150 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330119 | 0.91 | MET (0.47) | MAP4K1METTNK2CCNCCDK8 | |
| SCHEMBL12524281 | 0.85 | MAP4K1 (0.47) | MAP4K1METFGFR1FGFR2FGFR3 | |
| SCHEMBL2321632 | 0.84 | MET (0.47) | METTNK2CCNCCDK8FGFR1 | |
| SCHEMBL13978015 | 0.83 | MET (0.46) | MAP4K1METTNK2CCNCCDK8 | |
| SCHEMBL12527177 | 0.83 | MAP4K1 (0.58) | MAP4K1METJAK2JAK3 | |
| SCHEMBL319837 | 0.79 | CCNC (0.49) | METTNK2CCNCCDK8FGFR1 | |
| SCHEMBL320524 | 0.78 | CCNC (0.46) | METTNK2CCNCCDK8FGFR1 | |
| SCHEMBL12524282 | 0.77 | MET (0.49) | MAP4K1METFGFR1FGFR2FGFR3 | |
| SCHEMBL12495426 | 0.77 | MAP4K1 (0.51) | MAP4K1METCCNCCDK8KDR | |
| SCHEMBL2323319 | 0.75 | MET (0.43) | MAP4K1METFGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051318-B2 | Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051318-B2 | Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051318-B2 | Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2683715-B1 | PYRIDO[2,3-B]PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2683715-B1 | PYRIDO[2,3-B]PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2683715-A1 | PYRIDO [2, 3 - B]PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | Merck Patent GmbH (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-20130345227-A1 | PYRIDO [2, 3 - B] PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| WO-2012119690-A1 | PYRIDO [2, 3 - B] PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345227-A1 | PYRIDO [2, 3 - B] PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | TGFBR1, TGFBR2, PDXK | MAP4K1 28/4885MET 653/4885TNK2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.